title: Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir.
abstract: The QRS interval of 56 out of 75 (74.7%) HIV-infected, drug-experienced patients (66.7% men) increased during treatment with boosted or unboosted atazanavir by a median 5 ms (interquartile range 0-9; P < 0.0001); the PR and the QTc intervals did not change significantly. New asymptomatic bundle branch blocks were observed in four patients; one subject with a baseline first-degree atrioventricular block developed symptomatic bradyarrhythmia while receiving atenolol. The electrocardiographic monitoring of patients treated with atazanavir seems advisable.
authors.affiliation: Divisione di Malattie Infettive, Istituto Scientifico San Raffaele, Milan, Italy.
authors.forename: Nicola
authors.initials: N
authors.lastname: Gianotti
authors.forename: Monica
authors.initials: M
authors.lastname: Guffanti
authors.forename: Laura
authors.initials: L
authors.lastname: Galli
authors.forename: Alberto
authors.initials: A
authors.lastname: Margonato
authors.forename: Giulia
authors.initials: G
authors.lastname: Chiaravalli
authors.forename: Alba
authors.initials: A
authors.lastname: Bigoloni
authors.forename: Adriano
authors.initials: A
authors.lastname: Lazzarin
authors.forename: Antonella
authors.initials: A
authors.lastname: Castagna
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D000069446:Atazanavir Sulfate; D002037:Bundle-Branch Block / Q000139:chemically induced*; D016903:Drug Monitoring / Q000379:methods; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000009:adverse effects* / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D000069446:Atazanavir Sulfate